Phage Therapy for Resistant Infections

Why does antibiotic resistance make phage therapy worth studying?

The CDC's COVID-19 and antimicrobial resistance overview describes a substantial loss of progress during the pandemic: resistant hospital-onset infections and associated deaths each increased by at least 15% between 2019 and 2020 across seven pathogens. Longer hospital stays, greater use of invasive devices, and disruptions to infection prevention contributed to the problem. These are historical findings, rather than newly measured October infection rates, but they explain the continuing need for additional treatment options. [CDC overview](https://www.cdc.gov/antimicrobial-resistance/data-research/threats/COVID-19.html)

Bacteriophages are viruses that infect bacteria. BX004-A combined three phages selected to attack Pseudomonas aeruginosa, a bacterium that can persist in the lungs of people with cystic fibrosis. Its targeted design also creates a practical limitation: a patient's bacterial strain must be susceptible to the selected phages. [BX004-A study](https://www.nature.com/articles/s41467-025-60598-4)

What did the BX004 studies show about benefits and risks?

The randomized, placebo-controlled study published in Nature Communications in July 2025 included nine adults with cystic fibrosis and chronic Pseudomonas infection. Participants continued inhaled antibiotics during the seven-day dosing period. Researchers reported acceptable initial tolerability and a possible reduction in sputum bacterial burden. The sample was too small to establish efficacy; these findings did not demonstrate fewer hospitalizations or improved survival. [Published trial](https://www.nature.com/articles/s41467-025-60598-4)

The later development history changes how those early findings should be interpreted. On December 8, 2025, manufacturer BiomX announced that it was discontinuing its phase 2b BX004 trial after an internal analysis found unexpectedly high rates of adverse events. The company also cited insufficient resources to investigate an alternative dosing or treatment strategy. Its announcement did not provide a complete comparative safety dataset, so it cannot establish the frequency or cause of individual harms. It does, however, make the earlier study insufficient grounds for describing the treatment as proven safe. [BiomX discontinuation announcement](https://ir.biomx.com/news-releases/news-release-details/biomx-announces-discontinuation-phase-2b-bx004-trial-following)

What would patients need before considering investigational phage treatment?

For an investigational product, the FDA recommends clinical-trial participation whenever feasible. Expanded access can sometimes provide another route for a serious or immediately life-threatening condition when satisfactory alternatives are unavailable. Access depends on more than medical need: a supplier must provide the product, a physician must oversee treatment, and applicable FDA and institutional review requirements must be met. Authorization for an individual patient does not establish that a product is effective or suitable for routine prescribing. [FDA expanded-access guidance](https://www.fda.gov/news-events/expanded-access/expanded-access-information-physicians)

The clinical implication of the BX004 experience is that future studies must establish patient benefits alongside bacterial effects. A lower bacterial count can support a biological explanation, but patients need evidence about breathing, exacerbations, treatment burden, and serious adverse events. One discontinued program cannot determine whether every phage approach will succeed or fail. It demonstrates why each formulation and dosing strategy needs its own rigorous evaluation before becoming a dependable treatment option.